8-K: bioAffinity Technologies' CyPath Lung Detects Early-Stage Lung Cancer Missed by Traditional Tests

bioAffinity Technologies' noninvasive CyPath Lung test successfully detected Stage 1A pulmonary mucinous adenocarcinoma in a high-risk individual, despite inconclusive traditional diagnostic methods.

Summary

• bioAffinity Technologies announced a case study where its CyPath Lung test detected Stage 1A pulmonary mucinous adenocarcinoma in a 62-year-old female patient with a history of heavy smoking and COPD.
• The patient's initial tests in 2022, including a PET scan and a blood-based risk test, suggested a low probability of cancer (PET showed low uptake, blood test reported 11% reduced malignancy risk).
• Serial LDCTs appeared stable through 2023, but a July 2024 scan showed a transition to a more solid nodule, raising clinical concern.
• The patient opted against further surveillance CTs and a follow-up PET scan, leading her physician to order CyPath Lung in March 2025.
• CyPath Lung result was 0.56, classified as "likely malignancy," prompting surgical consultation.
• Wedge resection in June 2025 confirmed Stage 1A invasive mucinous adenocarcinoma, a subtype often missed by standard imaging.
• CyPath Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy, incorporating a fluorescent porphyrin.
• Clinical study results for CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters.

Sentiment

Score: 9

Explanation: The filing presents a highly positive case study demonstrating the effectiveness of the company's flagship product, CyPath Lung, in detecting early-stage cancer missed by traditional methods. This highlights the product's value proposition and potential to improve patient outcomes significantly.

Positives

• CyPath Lung successfully detected Stage 1A lung cancer in a high-risk patient where traditional tests (PET scan, blood-based risk test, imaging) were inconclusive or suggested a low probability of cancer.
• The test provided "diagnostic clarity" enabling early intervention and curative surgery for a cancer subtype often missed by standard imaging.
• CyPath Lung is a noninvasive sputum test, offering a vital path forward for high-risk patients with inconclusive imaging or limited diagnostic options.
• The patient successfully quit smoking in March 2025, coinciding with the CyPath Lung test.
• Clinical study results demonstrate high performance: 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in high-risk patients with small lung nodules.

Risks

• The ability of CyPath Lung to indicate a high probability of lung cancer may not always be consistent.
• The benefits of adding CyPath Lung to the standard of care for evaluating indeterminate lung nodules may not be consistently realized.
• CyPath Lung may not always provide clarity when imaging and risk models are inconclusive and when other adjuvant diagnostics are contraindicated.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent SEC filings could cause actual results to differ materially from current expectations.

Future Outlook

The company believes CyPath Lung can offer a vital path forward for high-risk patients with inconclusive imaging or limited diagnostic options, and that every early diagnosis is a life potentially saved. They also state that CyPath Lung can indicate a high probability of lung cancer, provide benefits when added to standard care for indeterminate lung nodules, and offer clarity when other diagnostics are inconclusive or contraindicated.

Management Comments

• "CyPath Lung gave us the diagnostic clarity we needed to intervene before this cancer progressed further." Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer.
• "This patient had low PET uptake, low serum marker risk, and gaps in imaging. CyPath Lung helped identify a relatively rare cancer that may have otherwise gone untreated." Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer.
• "Once again, CyPath Lung has demonstrated that it can detect lung cancer at Stage 1A when traditional diagnostic tests indicated a low probability of cancer." Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer.
• "For high-risk patients with inconclusive imaging or limited diagnostic options, we believe that our noninvasive test can offer a vital path forward." Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer.
• "Every early diagnosis is a life potentially saved, and that’s the promise CyPath Lung seeks to deliver on every day." Maria Zannes, President and CEO of bioAffinity Technologies.

Industry Context

This announcement highlights the ongoing challenge in early lung cancer detection, particularly for subtle or rare subtypes like mucinous adenocarcinoma, which often evade traditional imaging and serum markers. CyPath Lung positions itself as a noninvasive solution addressing this diagnostic gap, potentially improving patient outcomes by enabling earlier intervention. The use of AI and flow cytometry aligns with broader trends in medical diagnostics leveraging advanced technologies for enhanced accuracy.

Comparison to Industry Standards

• CyPath Lung demonstrated superior detection capabilities compared to traditional diagnostic tests, including PET scans and blood-based risk tests, which indicated a low probability of cancer in the presented case.
• The case study specifically notes that pulmonary mucinous adenocarcinoma is "frequently missed by standard imaging."
• Clinical study results for CyPath Lung showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (<20mm), which are strong performance metrics for a noninvasive diagnostic test in this challenging area.

Stakeholder Impact

• Shareholders: Positive impact due to demonstrated product efficacy, potentially increasing market confidence and future revenue prospects.
• Patients: Significant positive impact by offering a noninvasive, accurate test for early lung cancer detection, leading to improved treatment outcomes and survival rates.
• Healthcare Providers: Provides a valuable diagnostic tool for high-risk patients with inconclusive results from traditional methods, aiding in earlier and more accurate diagnoses.

Key Dates

Recommendation

The filing provides compelling evidence of CyPath Lung's efficacy in detecting early-stage lung cancer, even when traditional methods fail. This successful case study validates the product's core value proposition, addresses a critical unmet medical need, and could significantly enhance the company's market position and future revenue potential. The ability to detect cancer at Stage 1A, leading to curative surgery, is a strong indicator of the product's life-saving impact and commercial viability.

Keywords

Lung cancer, early detection, noninvasive diagnostic, CyPath Lung, biotechnology, cancer screening, adenocarcinoma, sputum test, AI diagnostics, flow cytometry, oncology, medical diagnostics